Maze Therapeutics, Inc.
MAZE
$7.83
$0.233.03%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 167.50M | 167.50M | 165.00M | 82.50M | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 167.50M | 167.50M | 165.00M | 82.50M | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 167.50M | 167.50M | 165.00M | 82.50M | -- |
| SG&A Expenses | 26.42M | 25.91M | 24.81M | 24.71M | 24.61M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 109.91M | 103.24M | 101.74M | 100.14M | 98.55M |
| Operating Income | 57.59M | 64.26M | 63.26M | -17.64M | -98.55M |
| Income Before Tax | 53.40M | 56.68M | 56.96M | -21.73M | -100.42M |
| Income Tax Expenses | 1.17M | 1.45M | 1.73M | 863.00K | -- |
| Earnings from Continuing Operations | 52.23 | 55.23 | 55.24 | -22.59 | -100.42 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 52.23M | 55.23M | 55.24M | -22.59M | -100.42M |
| EBIT | 57.59M | 64.26M | 63.26M | -17.64M | -98.55M |
| EBITDA | 60.88M | 67.83M | 67.05M | -13.71M | -94.46M |
| EPS Basic | 1.52 | -7.94 | -17.65 | -30.76 | -43.88 |
| Normalized Basic EPS | 16.82 | 17.92 | 16.99 | -4.70 | -26.39 |
| EPS Diluted | -0.13 | -9.30 | -19.01 | -31.45 | -43.89 |
| Normalized Diluted EPS | 8.54 | 9.65 | 8.72 | -8.83 | -26.39 |
| Average Basic Shares Outstanding | 9.59M | 9.47M | 9.36M | 9.25M | 9.15M |
| Average Diluted Shares Outstanding | 11.40M | 11.29M | 11.17M | 10.16M | 9.15M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
